Editorial Board
Revision as of 18:27, 11 October 2021 by Warner-admin (talk | contribs)
Our editorial board is comprised of clinical and pharmacological experts, organized primarily by disease focus. Most disease types now have expert representation, but we are still looking for potential section or page editors. If you are interested, please feel free to contact us with any questions or inquiries, at [email protected].
Editor-in-Chief
 |
Peter C. Yang, MD Boston, MA  Hem_Onc
|
Dr. Yang is board certified in Hematology and Medical Oncology; he practices at an academically affiliated institution in Massachusetts. |
Deputy Editor
 |
Jeremy L. Warner, MD, MS, FAMIA, FASCO Vanderbilt University Nashville, TN Hemoncwarner |
Dr. Warner is board certified in Hematology, Medical Oncology, and Clinical Informatics; he practices at the Vanderbilt-Ingram Cancer Center. He is an associate professor at Vanderbilt University. |
Associate Editors
| Evidence-based Oncology | ||
|---|---|---|
 |
Bishal Gyawali, MD, PhD Queen’s University Kingston, Canada oncology_bg
|
Dr. Gyawali is an assistant professor in the Department of Public Health Sciences at Queen’s University, Kingston, Canada. He is an advocate of "cancer groundshot", a term he coined to imply that investment should be made on proven high-value interventions in cancer care that are easy to implement globally and are affordable. |
Section Editors
| Breast Oncology | ||
|---|---|---|
 |
H. Deepika Fernandes, MD, FACP Bismarck, ND |
Dr. Fernandes is board certified in Medical Oncology and Hematology; she practices at the Edith Sanford Breast Center at Sanford Health. She is a clinical associate professor at the University of North Dakota. |
| Dermatologic Oncology | ||
 |
Elizabeth Buchbinder, MD Boston, MA |
Dr. Buchbinder is board certified in Medical Oncology; she practices at the Dana-Farber Cancer Institute. She is an instructor at Harvard Medical School. |
| Endocrine Oncology | ||
| Unfilled | If you are interested, please feel free to contact us with any questions or inquiries, at [email protected]. | |
| Gastrointestinal Oncology | ||
 |
Neeta K. Venepalli, MD, MBA Chicago, IL |
Dr. Venepalli is board certified in Medical Oncology; she practices at UI Health. She is an associate professor at the University of Illinois at Chicago. |
| Genitourinary Oncology | ||
 |
Ali Raza Khaki, MD Palo Alto, CA |
Dr. Khaki is a clinical assistant professor at Stanford University. |
| Gynecologic Oncology | ||
 |
Summer B. Dewdney, MD Chicago, IL |
Dr. Dewdney is board certified in Gynecologic Oncology and Obstetrics and Gynecology; she practices at Rush Copley Medical Center. She is the Director of the Division of Gynecologic Oncology and an associate professor at Rush University. |
| Head & Neck Cancer | ||
 |
Michael K. Gibson, MD, PhD, FACP Nashville, TN mgibson21212 |
Dr. Gibson is board certified in Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an associate professor at Vanderbilt University. |
| Neuro-Oncology | ||
 |
Seema Nagpal, MD Palo Alto, CA |
Dr. Nagpal is board certified in Neurology and UCNS certified in Neuro-Oncology; she practices at Stanford Health Care. She is a clinical associate professor at Stanford University |
| Sarcoma | ||
 |
Elizabeth J. Davis, MD Nashville, TN ejdavis25
|
Dr. Davis is board certified in Medical Oncology; she practices at the Vanderbilt-Ingram Cancer Center. She is an assistant professor at Vanderbilt University. |
| Thoracic Oncology | ||
 |
Amit Kulkarni, MBBS University of Minnesota Minneapolis, MN AmitKulkarniMD
|
Dr. Kulkarni is board certified in Internal Medicine and board eligible in Medical Oncology; he practices and is an Assistant Professor of Medicine, Division of Hematology, Oncology and Transplantation at the University of Minnesota. |
| Acute Leukemias | ||
 |
Martin W. Schoen, MD, MPH Saint Louis University St. Louis, MO |
Dr. Schoen is board certified in Internal Medicine and board eligible in Hematology and Medical Oncology; he practices at the Saint Louis Veterans Affairs Medical Center. He is an assistant professor at Saint Louis University. |
| Myeloproliferative Neoplasms and Myelodysplastic Syndromes | ||
 |
Sanjay R. Mohan, MD, MSCI Nashville, TN |
Dr. Mohan is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
| Aggressive Lymphomas & Lymphoproliferative disorders | ||
 |
Tarsheen K. Sethi, MD, MSCI Yale University New Haven, CT tarsheen2
|
Dr. Sethi is board certified in Hematology and Medical Oncology; she practices at the Smilow Cancer Hospital at Yale New Haven. She is an assistant professor at Yale University. |
| Indolent Lymphomas | ||
 |
Sanjai Sharma, MD Visalia, CA |
Dr. Sharma is board certified in Hematology and Medical Oncology; he practices at the Sequoia Regional Cancer Center. |
| Plasma Cell Dyscrasias | ||
 |
Andrew J. Cowan, MD Seattle, WA andrewcowanmd |
Dr. Cowan is board certified in Hematology and Medical Oncology; he practices at the Seattle Cancer Care Alliance. He is an assistant professor at the University of Washington. |
| T-cell and NK-cell neoplasms | ||
 |
Bhagirathbhai Dholaria, MBBS Nashville, TN |
Dr. Dholaria is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
| Histiocyte Disorders | ||
 |
Gaurav Goyal, MD UAB Birmingham, AL GauravGoyalMD
|
Dr. Goyal is board certified in Hematology and Medical Oncology; he practices at UAB Medicine. He is an assistant professor at UAB (The University of Alabama at Birmingham). |
| Pediatric Leukemia & Lymphoma | ||
 |
Wayne H. Liang, MD, MS, FAMIA Atlanta, GA WayneLiangMD |
Dr. Liang is board certified in Pediatrics, Pediatric Hematology-Oncology, and Clinical Informatics; he practices at Children’s Healthcare of Atlanta. He is an Assistant Professor of Pediatrics at Emory University. |
| Pediatric Neuro-Oncology & Solid Tumors | ||
 |
Nikki M. Wood, DO Kansas City, MO WoodNikkiM |
Dr. Wood is board certified in Pediatrics and Pediatric Hematology-Oncology; she practices at Children's Mercy Kansas City. She is an Assistant Professor of Pediatrics at the University of Missouri-Kansas City School of Medicine |
| Immuno-Oncology | ||
 |
Meghan J. Mooradian, MD Boston, MA |
Dr. Mooradian is board certified in Medical Oncology; she practices at Massachusetts General Hospital. She is an instructor at Harvard Medical School. |
| Transplant | ||
 |
Talal Hilal, MD University of Mississippi Jackson, MS THilalMD
|
Dr. Hilal is board certified in Hematology and Medical Oncology; he practices at University of Mississippi Medical Center. He is an assistant professor at the University of Mississippi. |
| Classical Hematology | ||
 |
Benjamin Tillman, MD Nashville, TN |
Dr. Tillman is board certified in Hematology and Medical Oncology; he practices at the Vanderbilt-Ingram Cancer Center. He is an assistant professor at Vanderbilt University. |
Page Editors
- Ivy Abraham, MD (University of Chicago Ingalls Memorial Hospital, Harvey, IL)
- Jon Arnason, MD (Beth Israel Deaconess Medical Center, Boston, MA)
- Karine A. Darbinyan, MD (Montefiore Medical Center, Bronx, NY)
- Teja Ganta, MD (Icahn School of Medicine at Mount Sinai, Manhattan, NY)
- Laura S. Graham, MD (University of Colorado, Anschutz Medical Campus, Aurora, CO)
- Mary L. Kwok, MD, FACP (Seattle Cancer Care Alliance, Seattle, WA)
- Eric I. Marks, MD (Boston University, Boston, MA)
- Ryan Nguyen, DO (University of Illinois at Chicago, IL)
- Samuel M. Rubinstein, MD (University of North Carolina, Chapel Hill, NC)
- Nishi N. Shah, MD (Montefiore Medical Center, Bronx, NY)
- Risa L. Wong, MD (University of Washington; Fred Hutchinson Cancer Research Center, Seattle, CA)
COI Disclosures
Please see our conflict of interest page for more details.
| Name | Research funding | Other (honoraria, travel support, significant ownership interests, etc.) | Date of disclosure |
|---|---|---|---|
| Elizabeth Buchbinder | NIH; Trial funding to institution: Eli Lilly, Novartis, Partners therapeutics, Genentech, BVD | Consulting/Advisory Board: Novartis, Apexigen, Shionogi, BMS | April 15, 2021 |
| Bhagirathbhai Dholaria | Nothing to disclose | Consulting/Advisory Board: Takeda, Janssen, Jazz, Poseida, Angiocrine | April 2, 2021 |
| H. Deepika Fernandes | Nothing to disclose | Nothing to disclose | April 3, 2021 |
| Gaurav Goyal | Nothing to disclose | Nothing to disclose | April 1, 2021 |
| Laura Graham | Nothing to disclose | Nothing to disclose | Oct. 11, 2020 |
| Talal Hilal | Nothing to disclose | Nothing to disclose | Oct. 12, 2020 |
| Ali R. Khaki | NIH | Travel: BCAN; ASCO | Oct. 12, 2020 |
| Mary L. Kwok | Nothing to disclose | Nothing to disclose | April 1, 2021 |
| Wayne H. Liang | Nothing to disclose | Nothing to disclose | Oct. 12, 2020 |
| Eric Marks | Nothing to disclose | Nothing to disclose | Oct. 12, 2020 |
| Sanjay R. Mohan | Novartis, Celgene | Nothing to disclose | Dec. 31, 2020 |
| Meghan J. Mooradian | Nothing to disclose | Consultant and/or received honorarium from AstraZeneca, Nektar Pharmaceuticals, Immunai | Oct. 15, 2020 |
| Seema Nagpal | Trial funding to institution: Agios, PharmAbcine, Insightec, Berg, Inovio | Consulting: SeaGen, Novocure Steering Committee, Biocept Steering Committee; Guidelines: NCCN CNS committee, ARS-AUC CNS committee, ASTRO Brain metastases guideline committee | April 12, 2021 |
| Ryan Nguyen | Nothing to disclose | Nothing to disclose | Oct. 14, 2020 |
| Samuel R. Rubinstein | Nothing to disclose | Nothing to disclose | Oct. 11, 2020 |
| Martin Schoen | Nothing to disclose | Nothing to disclose | April 2, 2021 |
| Sanjai Sharma | Nothing to disclose | Nothing to disclose | April 12, 2021 |
| Benjamin F. Tillman | Nothing to disclose | Nothing to disclose | Oct. 11, 2020 |
| Jeremy L. Warner | AACR; NIH; Vanderbilt University | Travel: AACR; ASCO Ownership: HemOnc.org Consulting: Westat |
April 2, 2021 |
| Risa L. Wong | ASCO; Fred Hutchinson Cancer Research Center | Nothing to disclose | Oct. 11, 2020 |
| Peter C. Yang | Nothing to disclose | Ownership: HemOnc.org Stock: Merck, Pfizer |
Oct. 12, 2020 |